Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroartemisinin for Acne Vulgaris
NCT07007078Phase 1Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dihydroartemisinin in acne vulgaris, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Investigator's Global Assessment at 90 days. Started Jun 2025; status: recruiting.
02
Drugs
dihydroartemisinin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT07007078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007078.